Satellos Bioscience Inc

OTCQB:MSCLFUnited StatesView on Canadian Exchange

Nov 13, 2024

Show headlines and story abstract

• Satellos Bioscience Q3 Loss Widens on Higher R&D Expenses, from 8:13AM ET on Wednesday Nov 13, 2024 by MT Newswires

  8:13AM ET on Wednesday Nov 13, 2024 by MT Newswires
  Companies Mentioned: MSCL
  08:13 AM EST, 11/13/2024 (MT Newswires) -- Satellos Bioscience (MSCL.TO), which is developing medicines to treat degenerative muscle diseases, said its third-quarter net loss widened. The company said the net loss widened to $9 million, or $0.08 per...

• -- Satellos Bioscience Brief: Reported a Q3 net loss of $9.0 million; Provides Clinical Update, from 7:04AM ET on Wednesday Nov 13, 2024 by MT Newswires

  7:04AM ET on Wednesday Nov 13, 2024 by MT Newswires
  Companies Mentioned: MSCL
  07:04 AM EST, 11/13/2024 (MT Newswires) -- ...

• Press Release: Satellos Reports Q3 2024 Financial Results and Provides Clinical Update, from 7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones

  7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: MSCL
  
  This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding Satellos' momentum; expected timing regarding enrollment and dosing with respect to the Company's programs; the potential for SAT-3247 to represent a disease modifying approach to the therapeutic treatment of people living with Duchenne; anticipated benefits to patients from a small molecule treatment for Duchenne; the advancement SAT-3247 into clinical trials; the pharmacodynamic properties and mechanism-of-action of SAT-3247; the potential of our approach in other degenerative muscle diseases or in muscle injury or trauma; the general benefits of modulating stem cell polarity by administering small molecule drugs; its/their prospective impact on Duchenne patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally; the utility of regenerating muscle by modulating polarity; and Satellos' technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are "forward-looking information or statements." Often but not always, forward-looking information or statements can be identified by the use of words such as "shall", "intends", "anticipate", "believe", "plan", "expect", "intend", "estimate", "anticipate", "potential", "prospective" , "assert" or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results "may", "might", "can", "could", "would" or "will" be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), and the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management's ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks listed in the "Risk Factors" section of Satellos' Annual Information Form dated March 26, 2024 (which is located on Satellos' profile at www.sedarplus.ca). Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise